Evaluate the safety, immune response and reactogenicity of aH5N1 vaccination in adult (18 through 60 years of age) and elderly (≥61 years of age) subjects with and without immunosuppressive conditions.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Percentage of subjects achieving seroconversion*
Timeframe: day 43
Geometric mean ratios (GMRs) as determined by HI assay
Timeframe: day 43
Percentage of subjects with an HI titer ≥1:40
Timeframe: day 43
Solicited and unsolicited adverse events
Timeframe: day 202